Int. Journal of Clinical Pharmacology and Therapeutics, Volume 50 - July (510 - 513)

Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: A randomized double-blind study in 60 patients
Amir Feily1, Benafshe Dormanesh1, Ali Reza Ghorbani2, Zahra Moosavi3, Maryam Kouchak4, Bahman Cheraghian5, Seyed Seifollah Beladi Mousavi6, Abolfath Mehrabian3, Nastaran Ranjbari7
1 AJA University of Medical Sciences, Tehran, Iran, Jundishapur University of Medical Sciences, Department of Dermatology, Ahvaz, 2 Department of nursing, Gachsaran branch, Islamic Azad University, Gachsaran, 3 Department of Dermatology, 4 Nanotechnology Research Center, School of Pharmacy, 5 Abadan Faculty of Nursing, 6 Department of Internal Medicine, Faculty of Medicine, and 7 Department of Pathology, Jundishapur University of Medical Sciences, Ahvaz, Iran

Add to Cart  

 

DOI 10.5414/CP201629

Abstract

Background: Chronic kidney disease (CKD)-associated pruritus is a significant clinical symptom affecting more than 50% of patients on hemodialysis. The availability of effective therapeutic options for management of CKD-associated pruritus remains a treatment challenge. Objective: The aim of this study was to compare cromolyn sodium cream 4% with placebo for the treatment of renal pruritus. Methods: A randomized, double-blind, prospective, 4-week study was designed. 60 patients with ESRD in our dialysis ward were randomly allocated to cromolyn sodium cream 4% or placebo. All of them completed the study period and their pruritus levels were evaluated 5 times (before the start of the study and at the end of each week for 4 weeks) using a Visual Analogue Scale (VAS). Results: The average pruritus score before administration of the drug in cromolyn sodium 4% and placebo group had been 2.5 ± 1.1 and 2.7 ± 1.3, respectively. In the cromolyn sodium 4% group the average score of pruritus gradually reduced to 0.3 ± 1.3 and in the placebo group it gradually decreased to 1.3 ± 1.4 at the end of Week 4. Method of t-test repeat analytical measurement indicated that there is no significant difference between reduction of pruritus in cromolyn 4% and placebo groups in the first and second week of the study, but in third and fourth week there were significant differences in reducing pruritus in favor of cromolyn sodium 4% (p < 0.04). Conclusion: According to our study cromolyn sodium cream 4% was more effective than placebo in reducing pruritus in uremic patients. We suggest to our colleagues to consider this treatment when facing a patient suffering from this symptom.

Author Details

Authors

Departments

  • 1 AJA University of Medical Sciences, Tehran, Iran, Jundishapur University of Medical Sciences, Department of Dermatology, Ahvaz,
  • 2 Department of nursing, Gachsaran branch, Islamic Azad University, Gachsaran,
  • 3 Department of Dermatology,
  • 4 Nanotechnology Research Center, School of Pharmacy,
  • 5 Abadan Faculty of Nursing,
  • 6 Department of Internal Medicine, Faculty of Medicine, and
  • 7 Department of Pathology, Jundishapur University of Medical Sciences, Ahvaz, Iran

Address

Amir Feily, MD
Department of Dermatology
Jondishapur University of Medical Sciences
Ahvaz, Iran
Email: [email protected]

Log in for Subscribers

Citation

Amir Feily, Benafshe Dormanesh, Ali Reza Ghorbani, Zahra Moosavi, Maryam Kouchak, Bahman Cheraghian, Seyed Seifollah Beladi Mousavi, Abolfath Mehrabian and Nastaran Ranjbari. Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: A randomized double-blind study in 60 patients. 2012; 50: 510-513. doi: 10.5414/CP201629.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart